Chlorpromazine versus clotiapine for schizophrenia

Mazhari, Shahrzad; Goughari, Ali S; Esmailian, Saeed; Shah-Esmaili, Armita

doi:10.1002/14651858.cd011810

Cited by 5 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our systematic search of the Cochrane Database of Systematic Reviews yielded a total of 37 Cochrane systematic reviews (28 for SGAs), 15 –50 which generated 316 informative randomised controlled trials (243 for SGAs). Most of these studies did not include children or adolescents; 0% to 5% of studies included patients below 18 years of age, of which fewer than 10% were below the age of 18 years.…”

Section: Resultsmentioning

confidence: 99%

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine. We used a random effects model because of the heterogeneity between-studies in drug dosage and method of ascertainment of movement disorders. Our systematic search yielded 37 Cochrane systematic reviews (28 for SGAs), which generated 316 informative randomised controlled trials (243 for SGAs). With respect to SGAs, prevalence estimates ranged from 1.4% (quetiapine) to 15.3% (L-sulpiride) for dystonia, 3.3% (paliperidone) to 16.4% (L-sulpiride) for akathisia, 2.4% (asenapine) to 29.3% (L-sulpiride) for parkinsonism, and 0.2% (clozapine) to 28.2% (L-sulpiride) for tremor. Prevalence estimates were not influenced by treatment duration, the use of a flexible or fixed dosing scheme, or whether studies used validated instruments for the screening/rating of movement disorders. Overall, we found high overlap on the prevalence of new-onset movement disorders across different SGAs precribed for established psychoses. Variations in prevalence figures across antipsychotic medications were observed for the different movement disorders. Differences in pharmacological properties, such as for the dopamine D R association rate and serotonin 5-HT antagonism, could contribute to this variation.

show abstract

Section: Resultsmentioning

confidence: 99%

Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…CPZ also inhibits other receptors, including receptors for 5-HT, H1 histamine, α1 and α2 adrenaline, and M1 and M2 muscarinic acetylcholine receptors [29][30][31] . Because of its versatile pharmacological profile, CPZ has been used for various diseases such as porphyria, tetanus, severe anxiety, psychotic aggression, refractory hiccups, severe nausea/emesis, insomnia, and severe pruritus 32,33 . In this study, we utilized CPZ in experiments to test its properties as an inhibitor of CCV formation 25 and to our surprise, we observed that CPZ inhibited the growth/survival of AML cells with MT-RTKs, while it showed minor effects on AML cells with WT-RTKs.…”

Section: Discussionmentioning

confidence: 99%

Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V

Rai

Tanaka

Suzuki³

et al. 2020

Nat Commun

View full text Add to dashboard Cite

Mutated receptor tyrosine kinases (MT-RTKs) such as internal tandem duplication of FMSlike tyrosine kinase 3 (FLT3 ITD) and a point mutation KIT D816V are driver mutations for acute myeloid leukemia (AML). Clathrin assembly lymphoid myeloid leukemia protein (CALM) regulates intracellular transport of RTKs, however, the precise role for MT-RTKs remains elusive. We here show that CALM knock down leads to severely impaired FLT3 ITDor KIT D814V-dependent cell growth compared to marginal influence on wild-type FLT3-or KIT-mediated cell growth. An antipsychotic drug chlorpromazine (CPZ) suppresses the growth of primary AML samples, and human CD34 + CD38-AML cells including AML initiating cells with MT-RTKs in vitro and in vivo. Mechanistically, CPZ reduces CALM protein at post transcriptional level and perturbs the intracellular localization of MT-RTKs, thereby blocking their signaling. Our study presents a therapeutic strategy for AML with MT-RTKs by altering the intracellular localization of MT-RTKs using CPZ.

show abstract